No Cheap Way Out for Affymetrix
This article was originally published in Start Up
Executive SummaryThe English High Court has ruled that Affymetrix's attempt to gain license to chip-making technology owned by Oxford Gene Technology (OGT), by making certain arrangements with Beckman Coulter, didn't work. It doesn't have any rights, the Justice says. Affymetrix will appeal, but UK-based OGT believes the California company's DNA chips definitely fall under the scope of its fundamental patent. OGT--which hopes to profit from its technology through out-licensing deals--expect that the UK decision will help it in the infringement suit it has brought against Affymetrix in the US. That case will be heard in October.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.